CRIS Current Research Information System

MANCUSO, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.961
EU - Europa 1.352
AS - Asia 775
AF - Africa 100
SA - Sud America 3
Totale 4.191
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.950
IT - Italia 410
GB - Regno Unito 267
CN - Cina 247
SG - Singapore 243
SE - Svezia 199
DE - Germania 153
VN - Vietnam 137
IN - India 94
IE - Irlanda 65
FR - Francia 40
RU - Federazione Russa 36
CI - Costa d'Avorio 34
TG - Togo 34
UA - Ucraina 33
BG - Bulgaria 28
BE - Belgio 22
ZA - Sudafrica 22
EE - Estonia 20
FI - Finlandia 20
JO - Giordania 15
NL - Olanda 13
CA - Canada 11
CH - Svizzera 11
ID - Indonesia 11
ES - Italia 10
NG - Nigeria 9
AT - Austria 7
PH - Filippine 7
JP - Giappone 5
CZ - Repubblica Ceca 4
IR - Iran 4
RO - Romania 3
RS - Serbia 3
TR - Turchia 3
LV - Lettonia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
BR - Brasile 1
CL - Cile 1
CY - Cipro 1
HK - Hong Kong 1
HU - Ungheria 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
LU - Lussemburgo 1
NO - Norvegia 1
PL - Polonia 1
PT - Portogallo 1
SC - Seychelles 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 4.191
Salva come PNG Salva come JPEG
Città #
Chandler 275
Southend 236
Singapore 215
Fairfield 199
Ashburn 151
Ann Arbor 115
Woodbridge 107
Bologna 106
Seattle 93
Wilmington 85
Houston 78
Santa Clara 75
Dublin 65
Boardman 61
Cambridge 61
Princeton 58
Dong Ket 57
Hyderabad 36
Abidjan 34
Lomé 34
Milan 29
Sofia 28
Bremen 27
New York 27
Turin 26
Beijing 25
Fabriano 22
Westminster 22
Brussels 21
Florence 21
Berlin 20
Jinan 20
Padova 20
Nanjing 18
Redmond 18
Helsinki 17
Los Angeles 17
Amman 15
San Diego 13
Jacksonville 12
Rome 12
Changsha 11
Jakarta 11
Falls Church 10
Redwood City 10
Abeokuta 9
Bern 9
Saint Petersburg 9
Shenyang 9
Guangzhou 8
Tianjin 8
Amsterdam 7
Medford 7
Nanchang 7
Paris 7
Parma 7
Salsomaggiore Terme 7
Vienna 7
Coimbatore 6
Dearborn 6
Jiaxing 6
Munich 6
Zhengzhou 6
Des Moines 5
Fuzhou 5
Monmouth Junction 5
Riola 5
Shanghai 5
Toronto 5
Ahmedabad 4
Como 4
Hebei 4
Kilburn 4
Leawood 4
Olalla 4
San Lazzaro Di Savena 4
Shenzhen 4
Tokyo 4
Wuhan 4
Belgrade 3
Boydton 3
Cagliari 3
Dongguan 3
Frankfurt am Main 3
Imola 3
Javea 3
Lappeenranta 3
Mülheim 3
Norwalk 3
Pianoro 3
Pune 3
Reggio Calabria 3
San Francisco 3
Springfield 3
Stilo 3
Taiyuan 3
Taizhou 3
Verona 3
Washington 3
Ankara 2
Totale 2.876
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 215
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 196
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 185
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 174
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 173
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 159
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 141
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 132
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 132
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 132
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 132
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 130
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 127
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 126
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 124
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 122
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 122
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 120
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 117
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 117
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 110
Role of consolidation therapy in transplant eligible multiple myeloma patients. 106
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 102
null 98
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 96
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 96
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 80
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 76
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 71
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 55
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 46
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 44
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 43
null 39
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 37
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 31
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 30
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 27
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 27
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 27
Pomalidomide combinations are a safe and effective option after daratumumab failure 26
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 25
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 23
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 22
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 21
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 21
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 19
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 19
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 13
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 13
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 12
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study 12
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents 10
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 9
Totale 4.362
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020595 0 0 0 0 80 70 96 104 91 64 50 40
2020/2021442 76 23 12 9 15 26 14 29 52 22 26 138
2021/2022748 70 38 42 70 58 23 18 53 29 92 126 129
2022/20231.010 83 140 36 151 74 96 27 56 164 28 98 57
2023/2024456 29 40 25 36 26 91 16 92 11 35 37 18
2024/2025725 114 176 162 141 132 0 0 0 0 0 0 0
Totale 4.362